

# Subject index of volume 24

- $\alpha$ -Amanitin 80
- Adenocarcinoma, gastric, advanced 67
- Adriamycin 33, 41, 264, 284
- Adriamycin-mitoxantrone 69
- Alkylating activity S 2, S 7
- Alternating regime 326
- Amphotericin B 181
- Amsacrin 123
- Amsacrine analog 230
- Analogues 28
- Angiotensin II 141
- ANLL 123
- Antagonist 193
- Anthracyclines 105, 284
- Antiemetic 45, 109, 307
- Antimetastatic action 302
- Antineoplastic activity 113
- Antitumor activity 181, 230, S 31
- Antitumor agent 15, 187
- Antitumor effects 15
- 5-Azacytidine 203
- BCNU 311
- Bioavailability 329
- Biodegradation 238
- Bioreductive alkylating agents 349
- Bone marrow S 16
- Bone marrow transplantation 321
- Breast cancer, advanced 261
- BRL43694A 193
- Busulfan 386
- Carbamoylation 95
- Carboplatin and ifosfamide 54
- Cardiac output 211
- Cardiotoxicity 211, 341, 395
- Carmethizole 277
- Cellular metabolism 155
- Chemosensitivity 87, 295
- Chemotherapy 109, 128, 141, 193, 261, 321, 378, S 16, S 45, S 48
- Chemotherapy, two-route 141
- Chest irradiation 128
- Children 123, 386, S 2, S 7, S 8, S 13, S 16, S 20, S 30
- Cimetidine 65
- Circadian rhythms 397
- Cisplatin (cis-platinum) 73, 109, 128, 135, 177, 256, 376, 381
- cis-Platinum-dextran complexes 161
- cis-Platinum (II) 141, 161
- Combination chemotherapy 69, 326, S 34
- Comparative study 105
- Continuous infusion 197
- Coumarin 65
- Cross-linking 311
- Cross-resistance 219, 311
- Cyclophosphamide S 48
- Cyclosporin A 284
- Cytosine arabinoside 203
- Cytotoxicity 80, 273, 291
- Cytotoxicity, of Ara C 251
- 0-Demethylation 172
- N-Demethylation 354
- Dexamethasone 359
- Diazepam 359
- Dicoumarol 349
- 5,6-Dihydro-5-azacytidine 155
- Dihydropyridines 367
- Dimethyl triazene 354
- Dipyridamole 181
- DMT benzoic acid 354
- DNA 155
- DNA drug adducts 311
- DNA methylation 203
- DNA synthesis 33
- Dog 277
- Dopamine 307
- Dose level 363
- Dose response 363
- Doxorubicin 225, 341
- Doxorubicin, continuous infusion 344
- Doxorubicin liposomes 341
- Drug administration 363
- Dual-parameter flow cytometry 291
- Egypt S 20
- Ehrlich ascites tumor 23
- Epirubicin 61, 211, 225, 332
- Escalating doses 61
- Ether lipids 58
- Etoposide 261, 329, 381
- Ewing's sarcoma S 40, S 45
- Flavone-8-acetic acid 15, 87, 269
- Flavone actiacid 273
- 5-Fluorouracil 9, 41, 67, 117, 197, 238
- 5-Fluorouridine 80
- Fredericamycin A 167
- Galactitol 311
- Gastric cancer 41
- Germ-cell tumors S 34
- Gluthatione 95
- Granisetron 45, 193
- Granulocyte 58
- GR38032F 137
- Hematologic malignancies 371
- Hemodiafiltration 400
- Hepatocellular carcinoma 50
- High-dose human tumor necrosis factor 391
- 5HT<sub>3</sub>-receptor 193
- Human leukemia cell 251
- Human lymphoid cells 155
- Human tumor cloning 230
- Hunan lung cancer 187
- 3-Hydroxytryptamine receptors 307
- Hyperthermia 172
- Hypoxia 349
- Ifosfamide 102, 137, 338, S 11, S 13, S 20, S 24, S 28, S 30, S 31, S 45, S 48
- Ifosfamide 395
- Ifosfamide, high-dose S 2, S 7, S 8, S 40
- Infusion time 256
- Interferon 393
- Interleukin-2 135
- Intraarterial 376
- Intracellular metabolites 73
- Intravenous 376
- Kinetic study 172
- L1210 cells 167
- Leukemia 225
- Lipid peroxidation 105
- Liposome entrapped cisplatin 1
- L-NDDP 1
- LNH 84 338
- Lower limb 393
- Lymph node metastases 393
- Lymphoblastic leukemia S 16
- Lymphocytic leukemia 203
- Macrophage 58
- Magnesium 109
- Malignant melanoma 65
- Malignant mesothelioma 133
- Mammary carcinoma 302
- Mechanism of action 269
- Melanotic melanomas 28
- Mesenchymal tumors S 30
- Mesna S 40
- Mesothelioma 329
- Metabolite 354
- Methotrexate 41, 67, 243, 338, 397, 400
- Misonidazole 172
- Mitomycin 102
- Mitomycin C 71, 349
- Mitomycin C, high-dose 50
- Mitoxantrone 105
- Mitozantrone 200
- Mouse 277
- Mouse liver 172
- MTT 295
- Multidrug resistance 284, 367
- Murine colon tumours 87
- Murine sarcoma 180 33
- Myeloblastic leukemia 71
- Nail toxicity 69
- Nasopharyngeal carcinoma 332
- Nausea 137
- Nephrotoxicity 341
- Non-Hodgkin's lymphoma 326, 338, S 20
- Nonlinearity 15
- Non small cell lung cancer 102
- N4-Palmitoyl-l- $\beta$ -D-arabinofuranosylcytosine 371
- Nude mice 148, 187
- Orphenadrine hydrochloride 359
- Osteosarcoma 376
- Ovarian cancer 54, 200, 256
- Paediatric malignant solid tumors S 24
- Paediatric oncology S 34, S 45
- Paediatric patients S 11
- Paediatric tumors S 28
- Pharmacodynamics 203, 314, 332
- Pharmacokinetics 15, 28, 45, 135, 225, 233, 277, 332, 354, 371, 386, 397
- Pharmacology 117
- Pharmacology, clinical 314
- Phase I trial 113, 233
- Phenantolamine 233
- Platinum disposition 376
- P388 leukemia cells 264
- P388 mouse leukemia 367
- Progenitor cells 58
- Pyrazoloacridines 219

## X

- Radiation 349  
Radiotherapy 102  
Rat jejunum 238  
Rat kidney 73  
Receptor antagonist 45  
Renal toxicity 243  
Response rate 187  
Rhabdomyosarcoma S 30, S 48  
Rh(I) complexes 302  
RNA polymerase 80  
Route of administration 211  
RSU 28  
  
Salivary passage 197  
Sertoli cell dysfunction 177  
Serum protein binding 161  
  
Small-cell lung cancer 321, 381  
Small-cell lung cancer, extensive 128  
Solid tumors 269, 273, S 11, S 13  
  
Tallysomyacin S<sub>10</sub>b 113  
Teniposide 123  
6-Thioguanine 291  
Thiols 95  
Thymidine 33  
Titanocene 23  
Topoisomerase 167  
Toxicity 1, 9, 50, 137, 332, S 8  
Trimetrexate 117, 246, 314  
T-2 toxin 264  
Tumor area 148  
Tumor cell immunogenicity 359  
  
Tumor cells 219  
Tumor growth 148  
  
Unbalanced growth 291  
Uridine, <sup>3</sup>H 295  
Uridine rescue 9  
Uroprotection S 40  
  
Verapamil 284  
Vincristine 133, S 30  
VP-16 128, 338  
  
Wilms' tumor, relapsed S 31  
  
Xenogenization 359  
  
Zinc acetate 177

